Cytochrome P450 2A6 whole-gene deletion (CYP2A64 ) polymorphism reduces risk of lung cancer: A meta-analysis

• Published in: Tobacco induced diseases Vol. 18; no. June
• Main Authors: Johani, Fadzrul, Majid, Mohd, Azme, Muhammad, Nawi, Azmawati
• Format: Journal Article
• Language: English
• Published: Heraklion European Publishing 01-06-2020; European Publishing on behalf of the International Society for the Prevention of Tobacco Induced Diseases (ISPTID)
• Subjects: Age; Carcinogens; Case studies; cyp2a64; Cytochrome; Cytochrome P450; cytochrome p450 2a6; Cytochromes P450; Gene deletion; Gene polymorphism; Genetic diversity; Health risks; Heterogeneity; Lung cancer; Meta-analysis; Metabolic activation; Metabolic rate; Metabolism; Observational studies; Pathogenesis; Polymorphism; Quality assessment; Quality control; Review Paper; Risk; Risk reduction; Smoking; Tobacco; Xenobiotics; Italy; Bangladesh; China; Japan
• ISSN: 1617-9625; 2070-7266; 1617-9625
• DOI: 10.18332/tid/122465

Introduction: Lung cancer is the most commonly diagnosed cancer worldwide and is the leading cause of cancer death. Smoking is a major contributor to the pathogenesis of lung cancer. Cytochrome P450 2A6 (CYP2A6) is responsible for the metabolic activation of most tobacco carcinogens. CYP2A6 genetic polymorphism can cause variations in the human metabolism of xenobiotics. We performed this meta-analysis to determine the association between whole-geneCYP2A6 deletion polymorphism (CYP2A6*4) and lung cancer risk. Methods: The PubMed, SAGE, Science Direct, the Cochrane Library and Ovid databases were searched for observational studies before October 2018. Methodological quality was assessed using the Newcastle-Ottawa Quality Assessment Scale (NOS). Results: Nine case-control studies involving 4385 lung cancer cases and 4142 controls were included in the analysis. The random-effects model was used to combine results from individual studies. The pooled odds ratio was 0.39 (95% CI: 0.27 – 0.56). There was no heterogeneity across studies (χ2=2.49, p=0.96, I2=0%). Conclusions: Current evidence from the case-control studies suggests that theCYP2A6 whole-gene deletion polymorphism decreases the risk of lung cancer. Further research is needed to identify any potential confounding factors that may impact this association.